Accesso libero

Off-Vertical Axis Rotational Assessment of Transdermal Scopolamine for Motion Sickness Prophylaxis

Daniel Woodard
Daniel Woodard
, 
Glenn Knox
Glenn Knox
, 
Scott Wood
Scott Wood
 e 
Cathy DiBiase
Cathy DiBiase
   | 02 mar 2022
Gravitational and Space Research's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Article Category: Research Article
Pubblicato online: 02 mar 2022
Pagine: 13 - 20
DOI: https://doi.org/10.2478/gsr-2014-0014
Parole chiave
© 2014 Daniel Woodard et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

JSC rotator with subject; schematic of OVAR angle.
JSC rotator with subject; schematic of OVAR angle.

Figure 2

Average symptom score (y-axis) versus elapsed time (x-axis). Series 1 is placebo, Series 2 is the 0.75 mg dose, and Series 3 is the 1.5 mg dose. Data was not collected at minute 17 since subjects egressed the chair at that time period. Data after minute 17 represents continued reporting of symptoms after the rotational stimulus was stopped. Averages of the 0–4 scale can, of course, yield non-integer values. These results were significant to the 0.05 confidence level.
Average symptom score (y-axis) versus elapsed time (x-axis). Series 1 is placebo, Series 2 is the 0.75 mg dose, and Series 3 is the 1.5 mg dose. Data was not collected at minute 17 since subjects egressed the chair at that time period. Data after minute 17 represents continued reporting of symptoms after the rotational stimulus was stopped. Averages of the 0–4 scale can, of course, yield non-integer values. These results were significant to the 0.05 confidence level.

Figure 3

Number of subjects reporting side effects at each dosage level. Note that half-dose side effects were reported by only one more subject than placebo (3 versus 2).
Number of subjects reporting side effects at each dosage level. Note that half-dose side effects were reported by only one more subject than placebo (3 versus 2).

Figure 4

Post-test nausea.
Post-test nausea.

Figure 5

Post-test fatigue.
Post-test fatigue.

j.gsr-2014-0014.tab.001

0:No abnormal sensations.
1:Abnormal sensations that do not cause noticeable discomfort, such as dizziness, unusual perspiration, and mild stomach awareness.
2:Mild discomfort, which is noticeable, but is not distracting and would not interfere, even with the performance of demanding tasks.
3:Moderate discomfort, which can be tolerated indefinitely, but is distracting and might affect one's ability to perform demanding tasks.
4:Severe discomfort, which cannot be tolerated indefinitely, or the feeling of impending vomiting.
eISSN:
2332-7774
Lingua:
Inglese
Frequenza di pubblicazione:
2 volte all'anno
Argomenti della rivista:
Life Sciences, other, Materials Sciences, Physics
Feed RSS della rivista